MedCap AB (publ) (MCAP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MedCap AB (publ) (MCAP) has a cash flow conversion efficiency ratio of 0.104x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr151.50 Million ≈ $16.30 Million USD) by net assets (Skr1.46 Billion ≈ $157.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MedCap AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how MedCap AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MCAP total liabilities for a breakdown of total debt and financial obligations.
MedCap AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MedCap AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhongzhu Medical Holdings Co Ltd
SHG:600568
|
0.016x |
|
MIPS AB
ST:MIPS
|
0.093x |
|
Feitian Technologies Co Ltd
SHE:300386
|
0.001x |
|
Zhejiang MustangBattery Co.Ltd
SHG:605378
|
-0.028x |
|
Suzhou Tianwo Science and Technology Co Ltd
SHE:002564
|
0.404x |
|
MBK Public Company Limited
BK:MBK-R
|
0.028x |
|
Grendene S.A
SA:GRND3
|
0.001x |
|
Karnov Group AB
ST:KAR
|
0.023x |
Annual Cash Flow Conversion Efficiency for MedCap AB (publ) (2007–2025)
The table below shows the annual cash flow conversion efficiency of MedCap AB (publ) from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see MedCap AB (publ) stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.46 Billion ≈ $157.00 Million |
Skr342.70 Million ≈ $36.88 Million |
0.235x | -15.94% |
| 2024-12-31 | Skr1.29 Billion ≈ $138.63 Million |
Skr360.00 Million ≈ $38.74 Million |
0.279x | +25.89% |
| 2023-12-31 | Skr1.03 Billion ≈ $110.53 Million |
Skr228.00 Million ≈ $24.54 Million |
0.222x | +122.94% |
| 2022-12-31 | Skr858.70 Million ≈ $92.41 Million |
Skr85.50 Million ≈ $9.20 Million |
0.100x | -40.27% |
| 2021-12-31 | Skr697.70 Million ≈ $75.08 Million |
Skr116.30 Million ≈ $12.52 Million |
0.167x | -13.19% |
| 2020-12-31 | Skr602.00 Million ≈ $64.78 Million |
Skr115.60 Million ≈ $12.44 Million |
0.192x | -10.50% |
| 2019-12-31 | Skr332.80 Million ≈ $35.81 Million |
Skr71.40 Million ≈ $7.68 Million |
0.215x | -35.16% |
| 2018-12-31 | Skr273.80 Million ≈ $29.47 Million |
Skr90.60 Million ≈ $9.75 Million |
0.331x | +224.47% |
| 2017-12-31 | Skr267.70 Million ≈ $28.81 Million |
Skr27.30 Million ≈ $2.94 Million |
0.102x | -63.41% |
| 2016-12-31 | Skr292.29 Million ≈ $31.45 Million |
Skr81.46 Million ≈ $8.77 Million |
0.279x | +675.70% |
| 2015-12-31 | Skr308.15 Million ≈ $33.16 Million |
Skr-14.92 Million ≈ $-1.61 Million |
-0.048x | -701.63% |
| 2014-12-31 | Skr280.63 Million ≈ $30.20 Million |
Skr2.26 Million ≈ $243.00K |
0.008x | +106.43% |
| 2013-12-31 | Skr221.92 Million ≈ $23.88 Million |
Skr865.00K ≈ $93.09K |
0.004x | -98.02% |
| 2012-12-31 | Skr195.48 Million ≈ $21.04 Million |
Skr38.55 Million ≈ $4.15 Million |
0.197x | +16.49% |
| 2011-12-31 | Skr169.82 Million ≈ $18.28 Million |
Skr28.75 Million ≈ $3.09 Million |
0.169x | -0.54% |
| 2010-12-31 | Skr179.99 Million ≈ $19.37 Million |
Skr30.64 Million ≈ $3.30 Million |
0.170x | +67.04% |
| 2009-12-31 | Skr169.94 Million ≈ $18.29 Million |
Skr17.32 Million ≈ $1.86 Million |
0.102x | +305.17% |
| 2008-12-31 | Skr134.11 Million ≈ $14.43 Million |
Skr3.37 Million ≈ $362.99K |
0.025x | +49.35% |
| 2007-12-31 | Skr127.44 Million ≈ $13.71 Million |
Skr2.15 Million ≈ $230.94K |
0.017x | -- |
About MedCap AB (publ)
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more